Neuroprotective effects of agomelatine and vinpocetine against chronic cerebral hypoperfusion induced vascular dementia

Current Neurovascular Research

Volumn 12, Issue 3, 2015, Pages 240-252

  Gupta, Surbhi ^a   Singh, Prabhat ^a   Sharma, Brij Mohan ^b   Sharma, Bhupesh ^a,b  

^a BHARAT INSTITUTE OF TECHNOLOGY   (India)

^b Dilshad Garden   (India)

Author keywords

2,3,5 triphenylterazolium chloride staining; Acetylcholinesterase; Brain damage; Melatonin receptor; Oxidative stress; Phosphodiesterase 1 enzyme; Two vessel occlusion

Indexed keywords

ACETYLCHOLINESTERASE; AGOMELATINE; CATALASE; GLUTATHIONE; MALONALDEHYDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VINPOCETINE; ACETAMIDE DERIVATIVE; NEUROPROTECTIVE AGENT; VINCA ALKALOID;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN DAMAGE; BRAIN INFARCTION SIZE; BRAIN PERFUSION; CAROTID ARTERY LIGATION; CAROTID ARTERY OBSTRUCTION; CHOLINERGIC ACTIVITY; COGNITIVE DEFECT; COMMON CAROTID ARTERY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ESCAPE BEHAVIOR; LEARNING DISORDER; LIPID PEROXIDATION; MALE; MORRIS WATER MAZE TEST; MOTOR PERFORMANCE; MOUSE; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TISSUE INJURY; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; COMPLICATION; DEMENTIA, VASCULAR; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; MAZE TEST; METABOLISM; PATHOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; TIME FACTOR;

ACETAMIDES; ACETYLCHOLINESTERASE; ANALYSIS OF VARIANCE; ANIMALS; ARTERIAL OCCLUSIVE DISEASES; BRAIN; CATALASE; DEMENTIA, VASCULAR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; MALE; MALONDIALDEHYDE; MAZE LEARNING; MICE; NEUROPROTECTIVE AGENTS; SUPEROXIDE DISMUTASE; TIME FACTORS; VINCA ALKALOIDS;

EID: 84937134206     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202612666150603130235     Document Type: Article

References (69)

1. de la Torre JC. Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia, Cardiovasc Psychiatry Neurol 2012; 2012: 367516.
2. Gupta S, Sharma B. Pharmacological modulation of I(1)-imidazoline and α2-adrenoceptors in sub acute brain ischemia induced vascular dementia. Eur J Pharmacol 2014a; 723:80-90.
3. Sudduth TL, Powell DK, Smith CD, Greenstein A, Wilcock DM. Induction of hyperhomocysteinemia models vascular dementia by induction of cerebral microhemorrhages and neuroinflammation. J Cereb Blood Flow Metab 2013; 33(5): 708-15.
4. Gupta S, Sharma B. Pharmacological benefit of agomelatine and vanillin in experimental model of Huntington's disease. Pharmacol Biochem Behav 2014b; 122C: 122-135.
5. Chen Y, Mancuso J, Zhao Z, et al. Vasodilation by in vivo activation of astrocyte endfeet via two-photon calcium uncaging as a strategy to prevent brain ischemia. J Biomed Opt 2013; 18(12): 126012.
6. Ji HJ, Hu JF, Wang YH, Chen XY, Zhou R, Chen NH. Osthole improves chronic cerebral hypoperfusion induced cognitive deficits and neuronal damage in hippocampus. Eur J Pharmacol 2010; 636(1-3): 96-101.
7. Xi Y, Wang M, Zhang W, et al. Neuronal damage, central cholinergic dysfunction and oxidative damage correlate with cognitive deficits in rats with chronic cerebral hypoperfusion. Neurobiol Learn Mem 2014; 109: 7-19.
8. Shu Y, Zhang H, Kang T, et al. PI3K/Akt signal pathway involved in the cognitive impairment caused by chronic cerebral hypoperfusion in rats. PLoS One 2013; 8(12): e81901.
9. Singh P, Gupta S, Sharma B. Melatonin receptor and KATP channel modulation in experimental vascular dementia. Physiol Behav 2015; 142: 66-78.
10. Chenu F, El Mansari M, Blier P. Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. Neuropsychopharmacol 2013; 38(2): 275-84.
11. Li DY, Smith DG, Hardeland R, et al. Melatonin receptor genes in vertebrates. Int J Mol Sci 2013; 14(6): 11208-23.
12. Pala D, Lodola A, Bedini A, Spadoni G, Rivara S. Homology models of melatonin receptors: challenges and recent advances. Int J Mol Sci 2013; 14(4): 8093-121.
13. Demyttenaere K. Agomelatine: a narrative review. Eur Neuropsychopharmacol 2011; 21 (4): S703-9.
14. Aguiar CC, Almeida AB, Araijo PV, et al. Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures. Cell Mol Neurobiol 2013; 33(6): 825-35.
15. Park JH, Shim HM, Na AY, et al. Melatonin prevents pancreatic β-cell loss due to glucotoxicity: the relationship between oxidative stress and endoplasmic reticulum stress. J Pineal Res 2013. doi: 10.1111/jpi.12106. PMID: 24168371.
16. Campolo M, Ahmad A, Crupi R, et al. Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury. J Endocrinol 2013; 217(3): 291-301.
17. Dagyte G, Luiten PG, De Jager T, et al. Chronic stress and antidepressant agomelatine induce region-specific changes in synapsin I expression in the rat brain. J Neurosci Res 2011; 89(10): 1646-57.
18. Lee CH, Yoo KY, Choi JH, et al. Melatonin's protective action against ischemic neuronal damage is associated with up-regulation of the MT2 melatonin receptor. J Neurosci Res 2010; 88(12): 2630-40.
19. Das A, McDowell M, Pava MJ, et al. The inhibition of apoptosis by melatonin in VSC4.1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-alpha toxicity involves membrane melatonin receptors. J Pineal Res 2010; 48(2): 157-69.
20. Srinivasan V, Pandi-Perumal SR, Maestroni GJ, Esquifino AI, Hardeland R, Cardinali DP. Role of melatonin in neurodegenerative diseases. Neurotox Res 2005; 7(4): 293-318.
21. Vereczkey L. Review Pharmacokinetics and metabolism of vincamine and related compounds. Eur J Drug Metab Pharmacokinet 1985; 10(2): 89-103.
22. Nivison-Smith L, Acosta ML, Misra S, O'Brien BJ, Kalloniatis M. Vinpocetine regulates cation channel permeability of inner retinal neurons in the ischaemic retina. Neurochem Int 2014; 66: 1-14.
23. Lakics V, Karran EH, Boess FG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacol 2010; 59(6): 367-74.
24. Medina AE. Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions. Front Neurosci 2011; 5: 21.
25. Horváth S.The use of vinpocetine in chronic disorders caused by cerebral hypoperfusion. Orv Hetil 2001; 142(8): 383-9.
26. Filimonov VA, Kliueva VN, Kondrasheva IN. Vinpotropile in the treatment of cerebral vascular diseases. Zh Nevrol Psikhiatr Im S S Korsakova 2007; 107(2): 58-60.
27. Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc 1987; 35(5): 425-30.
28. DeNoble VJ. Vinpocetine enhances retrieval of a step-through passive avoidance response in rats. Pharmacol Biochem Behav 1987; 26(1): 183-6.
29. Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol 1991; 6(1): 31-43.
30. Herrera-Mundo N, Sitges M. Vinpocetine and α-tocopherol prevent the increase in DA and oxidative stress induced by 3-NPA in striatum isolated nerve endings. J Neurochem 2013; 124(2): 233-40.
31. Deshmukh R, Sharma V, Mehan S, Sharma N, Bedi KL. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine - a PDE1 inhibitor. Eur J Pharmacol 2009; 620(1-3): 49-56.
32. Valikovics A. Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. Ideggyogy Sz 2007; 60(7-8): 301-10.
33. Dazsi L, Kis-Varga I, Nagy J, Komlodi Z, Kárpáti E. Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke. Acta Pharm Hung 2002; 72(2): 84-91.
34. Gupta S, Sharma B, Singh P, Sharma BM. Modulation of Transient Receptor Potential Vanilloid Subtype 1 (TRPV1) and Norepinephrine Transporters (NET) Protect Against Oxidative Stress, Cellular Injury, and Vascular Dementia. Curr Neurovasc Res 2014; 11(2): 94-106.
35. Gupta S, Sharma B. Protective effects of phosphodiesterase-1 (PDE1) and ATP sensitive potassium (KATP) channel modulators against 3-nitropropionic acid induced behavioral and biochemical toxicities in experimental Huntington's disease. 2014c; 732: 111-22.
36. Sharma B, Sharma PM. Arsenic toxicity induced endothelial dysfunction and dementia: pharmacological interdiction by histone deacetylase and inducible nitric oxide synthase inhibitors. Toxicol Appl Pharmacol 2013; 273(1): 180-8.
37. Sharma B, Singh N. Pharmacological inhibition of inducible nitric oxide synthase (iNOS) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, convalesce behavior and biochemistry of hypertension induced vascular dementia in rats. Pharmacol Biochem Behav 2013; 103(4): 821-30.
38. Sharma B, Singh N. Salutary effect of NFκB inhibitor and folacin in hyperhomocysteinemia-hyperlipidemia induced vascular dementia. Prog Neuropsychopharmacol Biol Psychiatry 2012a; 38(2): 207-15.
39. Sharma B, Singh N. Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats. Psychopharmacology (Berl) 2011a; 215(4): 677-87.
40. Sharma B, Singh N. Experimental hypertension induced vascular dementia: pharmacological, biochemical and behavioral recuperation by angiotensin receptor blocker and acetylcholinesterase inhibitor. Pharmacol Biochem Behav 2012b; 102(1): 101-8.
41. Sharma B, Singh N. Behavioral and biochemical investigations to explore pharmacological potential of PPAR-gamma agonists in vascular dementia of diabetic rats. Pharmacol Biochem Behav 2011b; 100(2): 320-9.
42. Singh P, Sharma B, Gupta S, Sharma BM. In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator. Psychopharmacol (Berl) 2015; 232(2): 465-75.
43. Gupta S, Sharma B. Pharmacological benefit of I1-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease. Brain Res Bull 2014d; 102: 57-68.
44. Sharma, B., Singh, N. (2012c). Defensive effect of natrium diethyldithiocarbamate trihydrate (NDDCT) and lisinopril in DOCA-salt hypertension-induced vascular dementia in rats. Psychopharmacol (Berl.) 223: 307-317.
45. Sharma B, Singh N. Defensive effect of natrium diethyldithiocarbamate trihydrate (NDDCT) and lisinopril in DOCA-salt hypertension-induced vascular dementia in rats. Psychopharmacol (Berl) 2012c; 223(3): 307-17.
46. Sharma B, Singh N. Pitavastatin and 4'-hydroxy-3'-methoxyacetophenone (HMAP) reduce cognitive dysfunction in vascular dementia during experimental diabetes. Curr Neurovasc Res 2010; 7(3): 180-91.
47. Shibata M, Yamasaki N, Miyakawa T, et al. Selective impairment of working memory in a mouse model of chronic cerebral hypoperfusion. Stroke 2007; 38(10): 2826-32.
48. Galisova A, Baciak L, Jozefovicova M, et al. Pathophysiological rat model of vascular dementia: magnetic resonance spectroscopy, microimaging and behavioral study. Brain Res 2014; 1568: 10-20.
49. Du J, Ma M, Zhao Q, et al. Mitochondrial bioenergetic deficits in the hippocampi of rats with chronic ischemia-induced vascular dementia. Neurosci 2013; 231: 345-52.
50. Kitamura A, Fujita Y, Oishi N, et al. Selective white matter abnormalities in a novel rat model of vascular dementia. Neurobiol Aging 2012; 33(5): 1012.e25-35.
51. Sakr HF, Khalil KI, Hussein AM, Zaki MS, Eid RA, Alkhateeb M. Effect of dehydroepiandrosterone (DHEA) on memory and brain derived neurotrophic factor (BDNF) in a rat model of vascular dementia. J Physiol Pharmacol 2014; 65(1): 41-53.
52. Cai QY, Chen XS, Zhan XL, Yao ZX. Protective effects of catalpol on oligodendrocyte death and myelin breakdown in a rat model of chronic cerebral hypoperfusion. Neurosci Lett 2011; 497(1): 22-6.
53. Xu B, Li XX, He GR, et al. Luteolin promotes long-term potentiation and improves cognitive functions in chronic cerebral hypoperfused rats. Eur J Pharmacol 2010; 627(1-3): 99-105.
54. Gumuslu E, Mutlu O, Sunnetci D, et al. The Antidepressant Agomelatine Improves Memory Deterioration and Upregulates CREB and BDNF Gene Expression Levels in Unpredictable Chronic Mild Stress (UCMS)-Exposed Mice. Drug Target Insights. 2014; 8: 11-21.
55. Yang R, Xiao HM, Huang D, Hu XW, Hu XL. Effects of melatonin on the induction of long term potentiation in the hippocampal CA3 area of rats. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2006; 22(2): 195-9.
56. Agrawal R, Tyagi E, Shukla R, Nath C. A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia. Neuropharmacol 2009; 56(4): 779-87.
57. Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev 2003; 1: CD003119.
58. Sierksma AS, Rutten K, Sydlik S, et al. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Neuropharmacol 2013; 64: 124-36.
59. Nyakas C, Felszeghy K, Szab R, et al. Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model. CNS Neurosci Ther 2009; 15(2): 89-99.
60. Korani MS, Farbood Y, Sarkaki A, Fathi Moghaddam H, Taghi Mansouri M. Protective effects of gallic acid against chronic cerebral hypoperfusion-induced cognitive deficit and brain oxidative damage in rats. Eur J Pharmacol 2014; 733C: 62-67.
61. Choi DH, Lee KH, Kim JH, et al. NADPH Oxidase 1, a Novel Molecular Source of ROS in Hippocampal Neuronal Death in Vascular Dementia. Antioxid Redox Signal 2014; 21(4): 533-50.
62. Li Y, He Y, Guan Q, Liu W, Han H, Nie Z. Disrupted iron metabolism and ensuing oxidative stress may mediate cognitive dysfunction induced by chronic cerebral hypoperfusion. Biol Trace Elem Res 2012; 150(1-3): 242-8.
63. Liu H, Zhang J. Cerebral hypoperfusion and cognitive impairment: the pathogenic role of vascular oxidative stress. Int J Neurosci 2012; 122(9): 494-9.
64. Wang F, Tian X, Zhang L, Tan D, Reiter RJ, Liu G. Melatonin promotes the in vitro development of pronuclear embryos and increases the efficiency of blastocyst implantation in murine. J Pineal Res 2013; 55(3): 267-74.
65. Kharwar RK, Haldar C. Daily variation in antioxidant enzymes and lipid peroxidation in lungs of a tropical bird Perdicula asiatica: role of melatonin and nuclear receptor RORα. Comp Biochem Physiol A Mol Integr Physiol 2012; 162(4): 296-302.
66. Feng Z, Lu Y, Wu X, et al. Ligustilide alleviates brain damage and improves cognitive function in rats of chronic cerebral hypoperfusion. J Ethnopharmacol 2012; 144(2): 313-21.
67. He XL, Wang YH, Bi MG, Du GH. Chrysin improves cognitive deficits and brain damage induced by chronic cerebral hypoperfusion in rats. Eur J Pharmacol 2012; 680(1-3): 41-8.
68. Ganzella M, de Oliveira ED, Comassetto DD, et al. Effects of chronic guanosine treatment on hippocampal damage and cognitive impairment of rats submitted to chronic cerebral hypoperfusion. Neurol Sci 2012; 33(5): 985-97.
69. Kilic U, Yilmaz B, Ugur M, et al. Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia. J Pineal Res 2012; 52(2): 228-35.